Analysts Set ProQR Therapeutics N.V. (NASDAQ:PRQR) Price Target at $7.14

Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) have received an average recommendation of “Moderate Buy” from the eight research firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $7.6667.

PRQR has been the topic of several research reports. Zacks Research upgraded shares of ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ProQR Therapeutics in a research report on Thursday, January 22nd.

ProQR Therapeutics Trading Up 6.2%

Shares of ProQR Therapeutics stock opened at $1.89 on Friday. The firm has a market cap of $198.85 million, a PE ratio of -4.02 and a beta of 0.21. The stock has a 50 day moving average of $1.66 and a 200 day moving average of $2.08. ProQR Therapeutics has a 12 month low of $1.07 and a 12 month high of $3.10.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in PRQR. Osaic Holdings Inc. grew its position in ProQR Therapeutics by 59.6% in the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 4,500 shares in the last quarter. Guggenheim Capital LLC purchased a new stake in ProQR Therapeutics during the fourth quarter valued at approximately $35,000. Moody Lynn & Lieberson LLC purchased a new stake in ProQR Therapeutics during the fourth quarter valued at approximately $50,000. Invesco Ltd. bought a new stake in shares of ProQR Therapeutics in the 4th quarter valued at approximately $51,000. Finally, Fifth Third Bancorp bought a new stake in shares of ProQR Therapeutics in the 3rd quarter valued at approximately $64,000. Institutional investors own 32.65% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.